IP Library Granted Patent US 11,833,219
Granted Patent B2
US 11,833,219 · App. 16/650,273 · Granted Dec 5, 2023

Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof

Inventors: Lele Li (Shandong, CN); Changjiang Huang (Shandong, CN); Youxiang Sun (Shandong, CN)
Assignee: MABPLEX INTERNATIONAL CO., LTD.
A61K47/6817A61K47/6811
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,833,219
App. No.
16/650,273
Granted
Dec 5, 2023
Kind
B2
Abstract

Provided is a method for producing an antibody-drug conjugate intermediate by addition of acid. An acid additive is used to convert the monomethyl auristatin derivative into a salt thereof to participate in the reaction. The addition of the acid additive can significantly improve the yield of the final product. In addition, the low price of the acid additive greatly reduces the production cost of the final ADC product. Moreover, the method of the present invention adopts a one-step preparation process, in addition to a higher yield of the final product, not only reducing the cost of the consumables, labor, equipment, site, raw materials and the like in the production, but also greatly reducing the production of the waste liquid, and thus reducing production costs and improving production efficiency, and making the method suitable for industrial large-scale production.

Claims (20)

1. A method for producing an antibody-drug conjugate intermediate by addition of acid, wherein the reaction scheme of the method is:

wherein

L is a linking group containing an acyl;

L′ is the residue of the linking group covalently attached to the monomethyl auristatin derivative;

solvent A and solvent B are polar or non-polar solvents; and the method comprises the following steps:

1) dissolving the linking group L, the condensing agent, and the organic base in the solvent A to obtain solution 1;

2) dissolving the monomethyl auristatin derivative and the acid in the solvent B to obtain solution 2; and

3) adding the solution 1 into the solution 2 to obtain the L′-monomethyl auristatin derivative via the condensation reaction between L and the monomethyl auristatin derivative;

wherein the molar amount of the organic base used in step 1) is greater than the molar amount of all free carboxyl group in the reaction system of step 3);

L is

the monomethyl auristatin derivative is MMAF,

the condensing agent is HATU,

the organic base is one or more selected from N,N-diisopropylethylamine and triethylamine,

the solvent A and the solvent B are each independently selected from DMF, DMA and DMSO,

the acid is one or more selected from trifluoroacetic acid, p-toluenesulfonic acid, trifluoromethanesulfonic acid, (−)-10-camphorsulfonic acid, (+)-10-camphorsulfonic acid and methanesulfonic acid, and

the molar ratio of the acid to the monomethyl auristatin derivative is greater than 1.

2. The method according to claim 1 , wherein the reaction scheme of the method is as follows:

3. The method according to claim 2 , wherein L′-MMAF is:

4. The method according to claim 1 , wherein the solution 1 is added into solution 2 evenly.

5. The method according to claim 1 , wherein the solution 1 is added into solution 2 by dropwise addition.

Assignments (2)
CHANGE OF NAME Recorded Mar 30, 2021
From: MABPLEX INTERNATIONAL, LTD.
To: MABPLEX INTERNATIONAL CO., LTD.
Reel/Frame 055851/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2020
From: LI, LELE; HUANG, CHANGJIANG; SUN, YOUXIANG
To: MABPLEX INTERNATIONAL, LTD.
Reel/Frame 052276/0272 →
Priority Claims (1)
CN 201910934570.0 · Sep 29, 2019 · national
Continuity (1)
Related Publication 20210393733A1 · Dec 23, 2021